Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Pharmaceuticals & Biotech
Create a narrative
Neurocrine Biosciences Community
NasdaqGS:NBIX Community
4
Narratives
written by author
0
Comments
on narratives written by author
78
Fair Values set
on narratives written by author
Create a narrative
Neurocrine Biosciences
Latest
Undervalued
Overvalued
Community Investing Ideas
Neurocrine Biosciences
AN
AnalystConsensusTarget
Consensus Narrative from 25 Analysts
Expanded Medicare Coverage And Trials Will Secure Patient Access
Key Takeaways Expansion in formulary coverage and Phase III programs strengthens future revenue potential through increased patient access and new product approvals. Solid cash reserves provide flexibility for growth investments, supporting long-term earnings and strategic business development initiatives.
View narrative
US$159.44
FV
20.6% undervalued
intrinsic discount
14.43%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
31
users have followed this narrative
3 days ago
author updated this narrative
Neurocrine Biosciences
AN
AnalystHighTarget
Consensus Narrative from 25 Analysts
INGREZZA Expansion And Aging Demographics Will Unlock New Markets
Key Takeaways Growth is driven by expanding flagship products into new patient segments, increased healthcare coverage, and strong adoption of new therapies for neurological disorders. Diversified late-stage pipeline and strategic investments in R&D, marketing, and business development support long-term revenue, margin, and portfolio growth.
View narrative
US$192.00
FV
34.1% undervalued
intrinsic discount
16.79%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
3 days ago
author updated this narrative
Neurocrine Biosciences
KA
kapirey
Community Contributor
Neurocrine Biosciences revenue will grow by 10% with Crenessity and Ingrezza sales if they can maintain the retail price.
Catalysts Pipeline Crenessity@ CRENESSITY Capsule 50/100 MG $766.66 packaging 50 MG 60u $45,999.60 packaging 100 MG 30u $22,999.80 Ingrezza@ Ingrezza (valbenazine) costs approximately $7,921 for 28 capsules of the 40mg strength and $8,702 for 28 capsules of the 80mg strength. INGREZZA Capsule 40 MG $310.80 INGREZZA SPRINKLE Capsule 40 MG $310.80 Other Products: Tetrabenazine Tablet 12.5 MG $62.52 Austedo Tablet 6 MG $100.06 Austedo XR Tablet 6 MG $100.06 Xenazine Tablet 12.5 MG $227.88 Assumptions Risks Risks and uncertainties associated with Neurocrine Biosciences' business and finances in general, risks and uncertainties associated with the commercialization of INGREZZA and CRENESSITY.
View narrative
US$153.97
FV
17.8% undervalued
intrinsic discount
10.00%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
7
users have followed this narrative
3 months ago
author updated this narrative
Neurocrine Biosciences
AN
AnalystLowTarget
Consensus Narrative from 25 Analysts
Regulatory And Competitive Pressures Will Diminish Future Prospects
Key Takeaways Heavy dependence on INGREZZA and CRENESSITY exposes the company to regulatory, reimbursement, and competition risks that could threaten revenue growth and margins. Intensifying competition, payer consolidation, and potential R&D setbacks may erode market share, pricing power, and future earnings.
View narrative
US$118.58
FV
6.7% overvalued
intrinsic discount
8.72%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 2 months ago
author updated this narrative
Your Valuation for
NBIX
NBIX
Neurocrine Biosciences
Your Fair Value
US$
Current Price
US$126.55
27.5% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-200m
4b
2015
2018
2021
2024
2025
2027
2030
Revenue US$4.1b
Earnings US$520.3m
Advanced
Set Fair Value